It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Mutations in the lamin A/C gene (LMNA) cause dilated cardiomyopathy associated with increased activity of ERK1/2 in the heart. We recently showed that ERK1/2 phosphorylates cofilin-1 on threonine 25 (phospho(T25)-cofilin-1) that in turn disassembles the actin cytoskeleton. Here, we show that in muscle cells carrying a cardiomyopathy-causing LMNA mutation, phospho(T25)-cofilin-1 binds to myocardin-related transcription factor A (MRTF-A) in the cytoplasm, thus preventing the stimulation of serum response factor (SRF) in the nucleus. Inhibiting the MRTF-A/SRF axis leads to decreased α-tubulin acetylation by reducing the expression of ATAT1 gene encoding α-tubulin acetyltransferase 1. Hence, tubulin acetylation is decreased in cardiomyocytes derived from male patients with LMNA mutations and in heart and isolated cardiomyocytes from Lmnap.H222P/H222P male mice. In Atat1 knockout mice, deficient for acetylated α-tubulin, we observe left ventricular dilation and mislocalization of Connexin 43 (Cx43) in heart. Increasing α-tubulin acetylation levels in Lmnap.H222P/H222P mice with tubastatin A treatment restores the proper localization of Cx43 and improves cardiac function. In summary, we show for the first time an actin-microtubule cytoskeletal interplay mediated by cofilin-1 and MRTF-A/SRF, promoting the dilated cardiomyopathy caused by LMNA mutations. Our findings suggest that modulating α-tubulin acetylation levels is a feasible strategy for improving cardiac function.
Lamin A/C gene mutations cause dilated cardiomyopathy associated with cofilin-1 phosphorylation and actin destabilization. Here, the authors show that phosphorylated cofilin-1 blunts the MRTF-A/SRF axis, leading to decreased tubulin acetylation and altered cardiac structure and function.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Chatzifrangkeskou, Maria 1 ; Macquart, Coline 1 ; Magiera, Maria M. 2
; Peccate, Cécile 1 ; Jouve, Charlène 3
; Virtanen, Laura 4 ; Heliö, Tiina 5 ; Aalto-Setälä, Katriina 6
; Crasto, Silvia 7 ; Cadot, Bruno 1 ; Cardoso, Déborah 1 ; Mougenot, Nathalie 8 ; Adesse, Daniel 9
; Di Pasquale, Elisa 7
; Hulot, Jean-Sébastien 3 ; Taimen, Pekka 10
; Janke, Carsten 2
; Muchir, Antoine 1
1 U974 SU-INSERM, Centre de recherche en Myologie, Paris, France (GRID:grid.418250.a) (ISNI:0000 0001 0308 8843)
2 CNRS UMR3348, Institut Curie, Université PSL, Orsay, France (GRID:grid.493838.d); CNRS UMR3348, Université Paris-Saclay, Orsay, France (GRID:grid.493838.d)
3 INSERM, Université de Paris, Paris Cardiovascular Research Center PARCC, Paris, France (GRID:grid.7429.8) (ISNI:0000000121866389)
4 University of Turku, Institute of Biomedicine and FICAN West Cancer Centre, Turku, Finland (GRID:grid.1374.1) (ISNI:0000 0001 2097 1371)
5 University of Helsinki, Heart and Lung Centre, Helsinki University Central Hospital, Helsinki, Finland (GRID:grid.7737.4) (ISNI:0000 0004 0410 2071)
6 Tampere University, Faculty of Medicine and Health Technology and BioMediTech Institute, Tampere, Finland (GRID:grid.502801.e) (ISNI:0000 0001 2314 6254)
7 National Research Council of Italy, Institute of Genetic and Biomedical Research (IRGB), UOS of Milan, Milan, Italy (GRID:grid.5326.2) (ISNI:0000 0001 1940 4177); Humanitas Clinical and Research Center-IRCCS, Rozzano (MI), Italy (GRID:grid.417728.f) (ISNI:0000 0004 1756 8807)
8 UMS28 Phénotypage du petit animal, Sorbonne Université, INSERM, Paris, France (GRID:grid.418250.a)
9 Laboratório de Biologia Estrutural, Fundação Oswaldo Cruz, Instituto Oswaldo Cruz, Rio de Janeiro, Brasil (GRID:grid.418068.3) (ISNI:0000 0001 0723 0931)
10 University of Turku, Institute of Biomedicine and FICAN West Cancer Centre, Turku, Finland (GRID:grid.1374.1) (ISNI:0000 0001 2097 1371); Turku University Hospital, Department of Pathology, Turku, Finland (GRID:grid.410552.7) (ISNI:0000 0004 0628 215X)




